Top

Category: Mergers and Acquisitions


Mergers and Acquisitions

NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement

July 26, 2022

Via: PMLiVE

Upon closing of the transaction, a newly formed holding company, NewAmsterdam Pharma Company NV, will be led by Michael Davidson, chief executive officer of the company. The Dutch biotech will receive approximately $235m from a private placement led by Frazier […]


Mergers and Acquisitions

After a lengthy drought, could biotech M&A be on the upswing?

July 8, 2022

Via: Biopharma Dive

Mergers and acquisitions in the pharmaceutical industry were more abundant in the second quarter than during the same period in years’ past, an uptick in activity that could help the sector rebound from a historic downturn. Between April and June, […]


Industry, Mergers and Acquisitions, Pharma, Vaccines

Preventing the next pandemic: Supporting early-stage R&D

July 7, 2022

Via: Pharmaphorum

When COVID-19 first emerged, scientists cautioned that developing an effective and safe vaccine could take longer than the commonly estimated figure of a year. The reason for the caution was that the previous quickest turnaround of a vaccine was for […]


Mergers and Acquisitions

Pfizer to Acquire Biohaven Pharmaceuticals for $11.7 Billion

May 16, 2022

Via: Biopharm International

Pfizer announced its $11.7 billion acquisition of Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company, on May 10, 2022. This acquisition will grant Pfizer the rights to rimegepant, a dual-acting migraine therapy approved in the United States for acute treatment and episodic […]


Mergers and Acquisitions

Pfizer to Acquire Biohaven Pharmaceuticals for $11.6 Billion

May 10, 2022

Via: Contract Pharma

Pfizer and Biohaven Pharmaceuticals have entered into an agreement under which Pfizer will acquire Biohaven, the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Pfizer will pay approximately […]


Mergers and Acquisitions

Regeneron to Acquire Checkmate Pharmaceuticals in $250M Deal

April 20, 2022

Via: Contract Pharma

Regeneron Pharmaceuticals, Inc. entered an agreement to acquire Checkmate Pharmaceuticals, Inc., a clinical stage biopharma company focused on technology to harness the immune system to combat cancer, for approximately $250 million in cash. Checkmate’s lead investigational candidate is vidutolimod, an […]


Mergers and Acquisitions

Fujifilm to Acquire Shenandoah Biotechnology

March 22, 2022

Via: Contract Pharma

Fujifilm Irvine Scientific, a provider of development and manufacturing of serum-free and chemically defined cell culture media for life science research, bioproduction and cell therapy manufacturing, will acquire Shenandoah Biotechnology, a manufacturer of recombinant proteins. Terms were not disclosed. Shenandoah […]


Mergers and Acquisitions

Pfizer and Acuitas Therapeutics Collaborate on Lipid Nanoparticle Delivery System

January 11, 2022

Via: Biopharm International

Pfizer and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, have entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive […]


Mergers and Acquisitions

Get ready for M&A: Large biopharma companies will have $1.7T in dealmaking firepower next year, analyst says

December 1, 2021

Via: FiercePharma

Merger and acquisition activity has been rather slow in the biopharma industry so far this year. But, by one team of analysts’ calculations, large drugmakers will have big piles of cash to deploy in 2022. Eighteen large-cap U.S. and European […]


Mergers and Acquisitions, News

Novartis Jumpstarts Presence in Protein Degradation with Up-to-$1.3B Dunad Collaboration

November 3, 2021

Via: Genetic Engineering and Biotechnology News

Novartis will partner with Dunad Therapeutics to develop oral covalent and protein degrading small molecule drugs for undisclosed diseases, through a collaboration that could generate more than $1.3 billion for the year-old developer of next-generation targeted protein degradation therapies—and revive […]


Mergers and Acquisitions

Aceto’s expansion roll continues with buyout of Irish biopharma manufacturer

October 14, 2021

Via: FiercePharma

Aceto continued its aggressive expansion plans with the acquisition of A&C Bio Buffer, marking the company’s sixth acquisition in under a year. A&C Bio, which is based in Limerick, Ireland, produces biological buffers, process solutions, cleaning solutions and chemical blends […]


Mergers and Acquisitions

Merck & Co. to Acquire Acceleron for $11.5B

September 30, 2021

Via: Genetic Engineering and Biotechnology News

Merck & Co. has agreed to acquire Acceleron Pharma for $11.5 billion, the companies said today, in a deal designed to bolster the buyer’s cardiovascular and blood drug portfolios with a Phase III pulmonary arterial hypertension (PAH)drug and a marketed […]


Mergers and Acquisitions

AstraZeneca moves deeper into rare diseases, spending $150M on late-phase hematology prospect

September 29, 2021

Via: FierceBiotech

AstraZeneca is continuing to build out its rare disease pipeline, pulling the trigger on an option to buy Caelum Biosciences that it picked up in its takeover of Alexion. The buyout gives AstraZeneca control of a phase 3 treatment for […]


Mergers and Acquisitions

Novartis acquires Arctos Medical to develop gene therapy programme

September 22, 2021

Via: European Pharmaceutical Review

Novartis have announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based Adeno-associated viruses (AAV) gene therapy programme and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition aims to more efficiently develop treatments for patients with vision loss […]


Mergers and Acquisitions

Boehringer Ingelheim to boost antibody discovery with partner Twist

September 10, 2021

Via: PMLiVE

Boehringer Ingelheim will use the same concept in a new research collaboration with San Francisco-based Twist Bioscience, harnessing its antibody libraries to discover therapeutic antibodies that work against a range of BI targets. Twist’s ability to manufacture DNA at scale […]


Mergers and Acquisitions

Roche bets on T-cell therapies with Adaptimmune deal

September 8, 2021

Via: PMLiVE

The deal with see Adaptimmune receive $150m upfront, another $150m over the next five years and then milestone payments potentially exceeding $3bn in aggregate sales, as well as royalties. Unlike other leaders in next-generation cell therapies, the partners will use […]


Mergers and Acquisitions

Pfizer swallows CD47 biotech Trillium in $2.3B takeover

August 23, 2021

Via: FierceBiotech

Biotechs targeting the “don’t eat me” signal cancer cells use to avoid the immune system are getting gobbled up. Pfizer is the latest company to buy its way into the space, splashing out $2.3 billion to acquire Trillium Therapeutics for […]


Mergers and Acquisitions

Lykan Bioscience and Vineti Partner to Advance Cell Therapies from Clinic to Commercialization

August 13, 2021

Via: Biopharm International

On Aug 12, 2021, Lykan Bioscience, a US-based contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, a US-based enterprise software platform company, announced a partnership that will combine Lykan’s purpose-built, multi-product cell therapy manufacturing facility located […]


Mergers and Acquisitions

Gilead-partnered Teneobio and its next-gen cancer work snapped up by Amgen for $2.5B

July 28, 2021

Via: FierceBiotech

Just two months after getting a swift approval for its closely watched KRAS lung cancer drug Lumakras, Amgen is not resting on its laurels and has penned a major new buyout deal to further boost its oncology pipeline. The biopharma […]


Mergers and Acquisitions

Regeneron, AZ team up on drugs for obesity “superpower” gene

July 27, 2021

Via: Pharmaphorum

AZ’s buy into the programme comes a few weeks after Regeneron published findings in the journal Science suggesting that people with certain GPR75 mutations have 54% reduced risk of obesity, based on sequencing data from almost 650,000 people in the […]